BioSpace News Archive

Ovid Therapeutics Inc. (NASDAQ: OVID) today announced that management will participant in a panel titled “Orphan Epilepsies” at the Cowen 43rd Annual Healthcare Conference in Boston, Massachusetts on March 6, 2023, at 12:50 p.m. ET.

Frontier Medicines Corporation announced the addition of Christo Shalish to the leadership team as senior vice president and head of business development.

Zevra Therapeutics, Inc. announced that it has become a Corporate Council member of the National Organization for Rare Disorders and reiterated its commitment to the rare disease community by celebrating Rare Disease Day 2023.

hC Bioscience, a pioneer in the development of tRNA-based therapeutics, received an investment from CureDuchenne Ventures, the strategic investment arm of CureDuchenne, a global nonprofit committed to finding and funding a cure for Duchenne muscular dystrophy.

Tempus, a leader in artificial intelligence (AI) and precision medicine, today announced a multi-year, strategic collaboration with Pfizer in which the two companies are working together to further AI and machine learning-driven efforts in therapeutic development.

Braxia Scientific Corp. (CSE: BRAX) (OTC Pink: BRAXF) (FSE: 4960) (“Braxia”, or the “Company”), a medical research company providing psychiatric, innovative ketamine and psilocybin treatments for mental health disorders, is pleased to announce that it has closed the first tranche of its non-brokered offering, as described in its press release of February 7, 2023

Mabwell (688062.SH), an innovative biopharmaceutical company with the layout of whole industry chain, announced that its IND application of its self-developed 9MW3811 injection for tumor and pulmonary fibrosis has been approved by the Therapeutic Goods Administration (TGA) in Australia.

Regulatory News: Median Technologies announces new and breakthrough results for its iBiopsy® Lung Cancer Screening AI/ML tech-based CADe/CADx1 Software as Medical Device to characterize malignant lung nodules in low dose CT scans.

ReCor Medical, Inc. (“ReCor”) and its parent company, Otsuka Medical Devices Co., Ltd. (“Otsuka Medical Devices”) today announced that primary endpoint results from the RADIANCE II pivotal trial were published in the Journal of the American Medical Association (JAMA).

DiscGenics, Inc. today announced that it will present at Canaccord Genuity’s 18th Annual Musculoskeletal Conference taking place in Las Vegas, NV on Tuesday, March 7, 2023.